Episode #393: Medical Mystery: The Man Who Got Weaker When He Started Training

Summary

A 43-year-old man starts exercising and ends up in the ER with a CK over 100x the upper limit of normal. His doctor says it’s from training. We don’t think so. In this episode, Dr. Jordan Feigenbaum and Dr. Austin Baraki walk through the full case — history, labs, diagnosis, and what actually went wrong — then break down the mechanisms behind the answer, the nocebo research, and what the brand-new 2026 guidelines mean for the 40 million Americans on a drug class you’ve definitely heard of.

We also cover the STOMP trial (do statins actually impair strength gains?), the SAMSON trial (how much of statin intolerance is nocebo?), the difference between myalgia, myositis, and rhabdomyolysis, Austin’s clinical approach to a patient whose strength is declining on a statin, and the treatment escalation pathway for statin-intolerant patients including bempedoic acid, PCSK9 inhibitors, and inclisiran. Plus, where GLP-1 receptor agonists like tirzepatide fit into the cardiovascular risk picture.

Full episode for Barbell Medicine Plus subscribers at https://barbellmedicine.supercast.com/

🎧 Listen on Apple Podcasts: https://podcasts.apple.com/au/podcast/medical-mystery-the-man-who-got-weaker-when-he/id1199780143?i=1000760107927

Key Takeaways

•  Statin myopathy is real but relatively uncommon. The excess symptom rate above placebo is roughly 1–5% in controlled trials. But in exercising patients, especially on combination therapy, the risk can be higher.
• There are three proposed mechanisms: reduced energy production from CoQ10 depletion, compromised muscle cell membranes from isoprenoid loss, and accelerated protein breakdown from calcium leak via the ryanodine receptor. Exercise amplifies all three, but the vast majority of people compensate.
• If you’re on a statin and your strength is going down, talk to your doctor before stopping the medication or changing your training. A CK test can help separate a drug problem from a programming problem
• The 2026 ACC guidelines list vigorous exercise as a risk factor for statin-associated muscle symptoms for the first time. They also provide statin-intolerant patients a clear escalation pathway: bempedoic acid, ezetimibe, PCSK9 inhibitors, and more.
• Lower is better for LDL. There’s a 33% relative reduction in cardiovascular events at <55 vs. 70 mg/dL. Lower for longer. Healthy lifestyle changes plus effective lipid-lowering therapy are among the best things you can do for cardiovascular risk.

Episode Timestamps

• 0:00 — A 43-year-old man is getting weaker, not stronger
• 2:09 — Taking the history: Medications, lifestyle, and red flags
• 12:53 — The labs come back: CK at 18,979
• 16:05 — Metabolic syndrome and the modern treatment approach
• 23:15 — Rhabdomyolysis: What it is and why it’s dangerous
• 29:50 — Final diagnosis and what went wrong with the medications
• 37:15 — 2026 ACC lipid guidelines: What changed
• 40:32 — Three mechanisms: How statins affect muscle
• 47:02 — The nocebo effect and the SAMSON trial
• 54:17 — Do statins impair training? The STOMP trial
• 1:00:30 — Who’s at highest risk for statin muscle problems
• 1:07:36 — What happened to the patient and options if this is you
• 1:14:12 — Five takeaways

Clinical Pearls

References

Guidelines

Blumenthal, Roger S., Pamela B. Morris, et al. “2026 ACC/AHA Guideline on the Management of Dyslipidemia.” Circulation, vol. 153, 2026. DOI: 10.1161/CIR.0000000000001423.

Primary Case

László, A., et al. “Exercise and Statin-Fibrate Combination Therapy-Caused Myopathy: A Case Report.” BMC Research Notes, vol. 6, no. 52, 2013. https://pubmed.ncbi.nlm.nih.gov/23388500/

LDL Targets

Lee YJ, et al. Ez-PAVE Investigators. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. N Engl J Med. 2026 Mar 28. doi: 10.1056/NEJMoa2600283. Epub ahead of print. PMID: 41910315.

Mechanisms of Statin Myopathy

Meador, Brandon M., and Karyn A. Huey. “Statin-Associated Myopathy and Its Exacerbation with Exercise.” Muscle & Nerve, vol. 42, no. 4, 2010, pp. 469–479. https://pubmed.ncbi.nlm.nih.gov/20878737/

Safitri, N., et al. “Statin-Induced Rhabdomyolysis: Mechanisms, Risk Factors, Management.” Drug, Healthcare and Patient Safety, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8593596/

Molinarolo, Steven et al. “Cryo-electron microscopy reveals sequential binding and activation of Ryanodine Receptors by statin triplets.” Nature communications vol. 16,1 11508. 20 Nov. 2025, doi:10.1038/s41467-025-66522-0

Thompson, Paul D., et al. “Lovastatin Increases Exercise-Induced Skeletal Muscle Injury.” Metabolism, vol. 46, no. 10, 1997, pp. 1206–1210.

Nocebo Effect and Statin Intolerance

Wood, Frances A., et al. “N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects (SAMSON).” New England Journal of Medicine, vol. 383, no. 22, 2020, pp. 2182–2184. https://pmc.ncbi.nlm.nih.gov/articles/PMC8453640/

Khan, Safi, et al. “Does Googling Lead to Statin Intolerance?” International Journal of Cardiology, vol. 262, 2018, pp. 25–27. https://pubmed.ncbi.nlm.nih.gov/29706390/

Gupta, Ajay, et al. “Adverse Events Associated with Unblinded, but Not with Blinded, Statin Therapy in the ASCOT-LLA.” Lancet, vol. 389, no. 10088, 2017, pp. 2473–2481. https://pubmed.ncbi.nlm.nih.gov/28476288/

Moon, James C., et al. “Examining the Nocebo Effect of Statins through Statin Adverse Events Reported in the FDA Adverse Event Reporting System.” Circulation: Cardiovascular Quality and Outcomes, vol. 14, no. 1, 2021, e007480. https://pubmed.ncbi.nlm.nih.gov/33161769/

Statins and Exercise Outcomes

Parker, Beth A., et al. “Effect of Statins on Skeletal Muscle Function.” Circulation, vol. 127, no. 1, 2013, pp. 96–103. https://pubmed.ncbi.nlm.nih.gov/23183941/

Parker, Beth A., and Paul D. Thompson. “Effect of Statins on Skeletal Muscle: Exercise, Myopathy, and Muscle Outcomes.” Exercise and Sport Sciences Reviews, vol. 40, no. 4, 2012, pp. 188–194. https://pmc.ncbi.nlm.nih.gov/articles/PMC3463373/

Mikus, Catherine R., et al. “Simvastatin Impairs Exercise Training Adaptations.” Journal of the American College of Cardiology, vol. 62, no. 8, 2013, pp. 709–714. https://pubmed.ncbi.nlm.nih.gov/23583255/

Slade, Jill M., et al. “The Impact of Statin Therapy and Aerobic Exercise Training on Skeletal Muscle and Whole-Body Aerobic Capacity.” American Heart Journal Plus: Cardiology Research and Practice, vol. 10, 2021, 100028. https://pmc.ncbi.nlm.nih.gov/articles/PMC8477381/

Gui, Ya-jun, et al. “Efficacy and Safety of Statins and Exercise Combination Therapy Compared to Statin Monotherapy in Patients with Dyslipidaemia: A Systematic Review and Meta-Analysis.” European Journal of Preventive Cardiology, vol. 24, no. 9, 2017, pp. 907–916. DOI: 10.1177/2047487317691874.

Genetic Susceptibility

SEARCH Collaborative Group. “SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study.” New England Journal of Medicine, vol. 359, no. 8, 2008, pp. 789–799.

Autoimmune Myopathy

Barkhordarian, M., et al. “Statin-Induced Autoimmune Myopathy.” American Journal of Case Reports, vol. 25, 2024, e944261. https://pubmed.ncbi.nlm.nih.gov/39219126/

Statin-Fibrate Interactions

Jones, Peter H., and Michael H. Davidson. “Reporting Rate of Rhabdomyolysis with Fenofibrate + Statin versus Gemfibrozil + Any Statin.” American Journal of Cardiology, vol. 95, no. 1, 2005, pp. 120–122.

Bruckert, Eric, et al. “Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients — The PRIMO Study.” Cardiovascular Drugs and Therapy, vol. 19, no. 6, 2005, pp. 403–414.

Sinzinger, Helmut, and John O’Grady. “Professional Athletes Suffering from Familial Hypercholesterolaemia Rarely Tolerate Statin Treatment Because of Muscular Problems.” British Journal of Clinical Pharmacology, vol. 57, no. 4, 2004, pp. 525–528.

Tirzepatide and GLP-1 Agonists

Al-kuraishy, Hayder M., et al. “The mechanistic role of tirzepatide in atherosclerosis: A review,.” International Journal of Biological Macromolecules, vol. 329, no. 1, 2025. https://doi.org/10.1016/j.ijbiomac.2025.147734.

“Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis.” 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11704219/

Hamidi, Hossein et al. “Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design.” American heart journal vol. 278 (2024): 24-32. doi:10.1016/j.ahj.2024.08.015

Fish Oil and Omega-3 Fatty Acids

Bhatt, Deepak L., et al. “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT).” New England Journal of Medicine, vol. 380, 2019, pp. 11–22. https://pubmed.ncbi.nlm.nih.gov/30415628/

Abdelhamid, Asmaa S., et al. “Omega-3 Fatty Acids for the Primary and Secondary Prevention of Cardiovascular Disease.” Cochrane Database of Systematic Reviews, 2020. https://pubmed.ncbi.nlm.nih.gov/32114706/

Manson, JoAnn E., et al. “Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL Trial).” New England Journal of Medicine, vol. 380, 2019, pp. 23–32. https://pubmed.ncbi.nlm.nih.gov/30415637/

Myopathy Classification

Selva-O’Callaghan, Albert, et al. “Statin-Induced Myalgia and Myositis: An Update on Pathogenesis and Clinical Recommendations.” Expert Review of Clinical Immunology, vol. 14, no. 3, 2018, pp. 215–224. https://pmc.ncbi.nlm.nih.gov/articles/PMC6019601/

Transcript

Cold Open

Alright. So we’ve got a guy, 43 years old, who recently decided to start exercising. He bought some dumbbells, started working out at home. And within about a week, he’s wrecked. Generalized soreness, legs feel heavy, nothing’s recovering. He told his GP, who said he’s probably just overdoing it and should back off.

So he backed off. And nothing changed.

Now, if you’ve been listening to this podcast for any amount of time, you know where we stand on overtraining syndrome. To our knowledge, nobody has ever produced it experimentally through resistance training. We’ve done episodes on this. What gets labeled OTS is almost always something else: not enough sleep, not enough food, too much life stress, a training-recovery mismatch. The symptoms are real. But the explanation is usually wrong.

So when someone walks in and the working diagnosis is “overtraining,” we want to look harder. And in this case, the actual answer is sitting right there, but it’s hidden behind the obvious one.

Segment 1 Why is this patient getting weaker the more he trains?

And to help us figure out why trying to get stronger is making this guy weaker, it’s the second most handsome doctor in North America, Dr. Austin Baraki.

Dr. Baraki, you’re in clinic. This is your next patient. Here’s what the referral says.

43-year-old man. BMI of 32, waist circumference 104 centimeters. He’s on medication for high blood pressure. Fasting glucose is high-normal. About a year ago, his GP ran a lipid panel and it came back ugly: total cholesterol 278, triglycerides 448, HDL 37. He was started on medication for the lipids at that point. He works a physical job in a warehouse, and recently decided to start training on top of that.

He’s here because his strength is going backward and nobody can tell him why.

I’m going to let you take a history. Ask me whatever you want and I’ll tell you what the patient says.

History role play: 

Medications: Fenofibrate 160 mg daily (started first, for the triglycerides). Atorvastatin 20 mg added about a month later (for the cholesterol). bystolic for blood pressure. No supplements. This is the first time the audience hears the word “statin.”

Training: Started about a week ago. Bought dumbbells, working out at home. All kinds of dumbbell work, upper and lower body. This is on top of a physical warehouse job where he does manual labor.

Symptoms: Moderate pain and stiffness everywhere: chest, arms, legs. Legs especially feel heavy and stiff. He assumed it was normal for someone just starting out.

Diet: Tried to cut calories previously but found it hard because his manual job made him hungry. Roughly 3 meals/day. Light alcohol, about 2 drinks/week.

Sleep: 6–7 hours. Says it’s been his normal for years.

Smoking: 25 pack-year history. Recently prescribed varenicline (Chantix) to quit. Took it for about 2 weeks, stopped on his own. He was briefly on statin + fibrate + varenicline simultaneously, though varenicline was stopped before symptoms started.

Family history: Hypertension, high cholesterol, and obesity in both parents. No known muscle diseases.

Other: No fever, no recent illness, no dark urine at this point (that detail comes in Segment 2). Cholecystectomy (gallbladder removal) in his 30s. Works a physical warehouse job.

Questions/Listener prompt

So now we’ve got the medication list. Austin, before I give you the labs, three questions.

One: Now that you have the full history, what are you most concerned about?

Two: He says he’s been sore since starting exercise. How do you think about sorting out normal new-exerciser soreness from something else?

Three: Anything on that medication list that makes you think twice?

So before we get into what went wrong, I want to sit with who this patient is for a second. Because I think people hear a case like this and think it’s some weird edge case. It’s not.

This is a 43-year-old guy with a BMI over 30, high triglycerides, blood pressure that needed medication, and a cholesterol panel that’s alarming enough that his doctor put him on two drugs for it. He smokes. He drinks a little. He works a physical job. And after getting some bad lab results, he did exactly what every doctor tells you to do — he started exercising.

That’s not exactly rare….well maybe the exercise part, but the patient here describes a huge chunk of the adult population in the US and globally. Metabolic syndrome alone — which is basically the cluster of things this guy has — affects about one in three American adults.

https://pubmed.ncbi.nlm.nih.gov/36906842

[AUSTIN RESPONDS] Austin — from a clinical standpoint, when you see a patient like this walk in, what’s on your radar? What are you most worried about long-term, and what does the medication strategy actually look like for someone with this many overlapping risk factors?

[After Austin answers]

Right, and that’s the thing. The whole point of treating this guy aggressively is that his cardiac risk is real. These aren’t vanity numbers. Triglycerides in the 400s, total cholesterol pushing 280 — the math on his 10-year cardiovascular risk is not good. His doctor is doing the right thing by stacking therapies. Statin for the LDL, fibrate for the triglycerides, blood pressure medication on top of that.

And the exercise piece is supposed to help with all of it. We know that. The guidelines say that. We say that on this show constantly. So this patient is doing everything he’s supposed to be doing. He’s taking his medications, he’s quitting smoking, and he’s getting off the couch.

And that’s what makes the next part of this case so important. Because something in that picture — in that combination of doing-all-the-right-things — goes sideways. 

And the question is whether anyone catches it in time, and whether this guy ends up trusting the medical system enough to keep going afterward.

That’s coming up next.

Segment 2-What does a CK of 19,000 tell you?

So we’ve got the history and the med list. Now let’s see the labs, because there’s a number on this panel that changes the entire conversation.

• Lipid panel: total cholesterol 250, triglycerides 154. Both down significantly from where he started, which was total cholesterol 278 and triglycerides 448. The medications are doing their job on the lipid side.
• And then there’s the CK.
  • Quick definition for anyone who hasn’t heard this term. CK stands for creatine kinase. It’s an enzyme that lives inside muscle cells. When muscle cells get damaged, CK leaks into the blood. The more damage, the higher the number. A normal CK is somewhere under 170 or so, depending on the lab.
  • This patient’s CK came back at 18,979.
  • That’s over 150 times the upper limit of normal.
• He came back to the office for a follow up, so he’s sitting in front of you. He says he feels fine, maybe a little sore. What’s going through your mind?

Now here’s something important. When we pushed harder on the history, the patient mentioned that right after he started working out with the dumbbells, he had about three days where everything hurt. Moderate pain everywhere, chest, arms, legs. His legs felt heavy and stiff. And he noticed dark-colored urine. But it resolved on its own, so he didn’t think it was worth mentioning. He kept going.

Austin, does that change your thinking about this patient?

• For our audience. We’ve covered rhabdomyolysis in detail on this podcast before. Rhabdomyolysis is what happens when muscle breaks down fast enough that the contents of the cells dump into the bloodstream.
  • One of those contents is a protein called myoglobin, and when myoglobin hits the kidneys in high enough concentrations, it can clog things up and cause acute kidney injury. That’s one of the things that makes rhabdo dangerous, along with electrolyte disturbances possibly causing an arrhythmia, the muscles swelling too much causing compartment syndrome, and so on. It’s not the muscle soreness per se
• A distinction we’ve made before that’s relevant here: there’s a difference between a high CK and actual rhabdomyolysis.
  • The term for a CK above five times the upper limit of normal is hyperCKemia. Being above five times normal doesn’t mean you have rhabdo. Athletes can blow past that number after a hard session and some people just have higher than normal CK responses to exercise, especially with new or eccentric-heavy training, and be totally fine.
  • But 18,979 is a different story. That’s 150 times normal, with a history of dark urine. At those levels, it’s more likely to be rhabdo and so we’d need to be concerned for myoglobin and the kidneys, as well as electrolytes and the heart. That’s rhabdomyolysis.

So before we get into what happened. Austin, Do you have a diagnosis?

Course: He was sent to the emergency care unit

• Both medications were stopped, the statin and the fibrate. They started IV saline to protect the kidneys. 
• On admission, his liver associated enzymes were also elevated: ALT 132, AST 248. Those are likely from the muscle damage, not the liver. We did a whole episode on how muscle breakdown produces elevated transaminases that get misattributed to the liver. 
• Same mechanism here, different trigger. Over the next several days, CK came down: 5,134, then 1,823. Transaminases started dropping too. Kidney function stayed normal throughout. He was discharged after two days.

Austin, I’ve got a different set of questions for you now.

One: How do you tell the difference between a drug side effect and the expected CK bump we’d see in any new exerciser?  

Two If you were this patient’s doctor at the time he said he wanted to start exercising, would you have done anything differently?

Three: Does having two medications instead of one matter here, or would the statin alone have been enough? tell the difference between a drug side effect and the expected CK bump we’d see in any new exerciser?  

One thing to mention. The 2026 ACC/AHA guidelines just replaced the 2018 cholesterol guidelines — first update in eight years. And for the first time, the new guideline explicitly lists vigorous exercise as a risk factor for statin-related muscle symptoms. That’s new. It wasn’t in the 2018 version. The entire section on managing statin muscle symptoms is new.

At the same time, the same guideline says routine CK monitoring in people taking statins who don’t have symptoms isn’t recommended. This patient had a CK of nearly 19,000 and was basically asymptomatic at the time of the lab draw. Under the current protocol, that number doesn’t get caught unless someone happens to order a CK for another reason — which is exactly what happened here. His doctor ordered routine bloodwork and stumbled into it.

So the guideline acknowledges the risk and also says don’t go looking for it. That’s not a contradiction, there are good reasons for it — false positives, cost, unnecessary anxiety. But this case shows you what can slip through that gap, though maybe it would’ve been fine.

Austin, what do you think- should this patient have been sent to the ER? Would you have sent him?

Segment 3 Mechanism of Statin

The medications were stopped and he recovered. Now the question is what was actually happening inside his muscle cells.

Understanding the mechanism matters here because it changes the differential. If this were too much exercise, you’d expect the symptoms to scale with the training — too much volume and intensity, not enough recovery, the muscle can’t keep up. Dial it back, recover, and you’re fine. The muscle itself is healthy, but you asked too much of it.

What’s different with statin myopathy is that the drug changes the muscle’s tolerance for work. The training load this guy took on — some dumbbell exercises at home — should have been completely manageable. It wasn’t, because the drug had exposed a vulnerability in the muscle that was already there, before he ever picked up a weight. 

When we come back from the break, we’ll get into the mechanism of how statins affect muscles, including whether or not they affect performance. 

**break**

Okay, we’re back on the Barbell Medicine podcast and we’re talking about how the cholesterol-lowering drugs statins affect muscles.

Statins work by blocking an enzyme called HMG-CoA reductase. You don’t need to remember that name. What matters is what the enzyme does: it sits at the top of a production line inside your cells. Think of it like a factory. The main product of that factory is cholesterol. Block the enzyme, the factory slows down, cholesterol production drops, the liver compensates by pulling more LDL, the “bad cholesterol,” out of the blood, and circulating LDL falls. That’s the intended effect. That’s why statins work and why they’re one of the most prescribed drug classes in the world. 

Quick detour on LDL targets, because this is new and directly relevant.

A trial published in the New England Journal of Medicine in March 2026 took patients with established cardiovascular disease and randomized them to a more aggressive LDL target, less than 55, versus less than 70. The group that hit the lower target had 33 percent fewer cardiovascular events over three years. In absolute terms, that’s 6.6 percent versus 9.7 percent, so about a 3-point absolute difference. The safety profile was similar between groups.

The 2026 guidelines reflect this. For the highest-risk patients, the LDL goal is now less than 55. For people with cardiovascular disease who aren’t in the very highest risk tier, less than 70. Both are lower than the 2018 targets. The takeaway is what we’ve said on this podcast before: for LDL, lower is better and the longer you maintain that lower level, the better. The evidence strongly supports the idea that your total lifetime exposure to the particles that build plaque drives cardiovascular disease. Bring that exposure down earlier and keep it down, and you reduce events.

So when we talk about statin myopathy, the answer isn’t to just abandon cholesterol-lowering treatment. The answer is to manage the side effects and find another path to the same target. And there are more tools for that now than there used to be. We’ll get to those.

Austin — when you’ve got a patient who’s having muscle symptoms on a statin but their cardiovascular risk genuinely warrants aggressive LDL lowering, how do you think through that tradeoff? Is it always try a different statin first, or are there cases where you’d go straight to a non-statin agent?

Back to the factory.

The problem is that the factory doesn’t only make cholesterol. It also makes a handful of other molecules that muscle cells depend on. When you slow the whole thing down with a statin, you reduce all of them. Researchers have identified several downstream effects that appear to contribute to muscle damage. I want to walk through three of the best-studied ones, with the caveat that much of this comes from animal models and cell culture work. The clinical picture in humans is consistent with these mechanisms, but we’re still connecting the dots.

First: the cell’s energy supply gets squeezed.

• One of the other products of that factory is a molecule called CoQ10, short for coenzyme Q10. CoQ10 works inside the mitochondria, the part of the cell that converts the food we eat into usable energy, which we know as ATP, the fuel your muscles run on.
• When statin use reduces CoQ10 levels, the proposed consequence is that the cell becomes less efficient at making energy.
• Muscle is one of the most energy-hungry tissues in the body. During a hard workout, ATP demand spikes. If a muscle cell starts with a lower energy ceiling because of reduced CoQ10, the gap between what the cell needs and what it can produce gets wider the harder you push. That’s the theory anyway
• Now, patients ask about CoQ10 supplements all the time, and the logic makes sense: if the statin is depleting it, why not just take more? The problem is the clinical trials haven’t backed it up. The evidence to date doesn’t show that supplementing CoQ10 reliably improves statin-related muscle symptoms. The 2026 guidelines specifically note it’s not recommended for this purpose. 

Austin, you get patients asking about CoQ10 for statin side effects. The mechanism sounds plausible, but the trial data isn’t really there yet. What’s your take?

• Second: the muscle cell’s outer membrane gets fragile.
  • That same factory also makes molecules that help hold cell membranes together. You might hear these called isoprenoids in the literature, but what matters is the job they do: they’re structural, like rebar in concrete. When statin use reduces them, the outer membrane of the muscle cell, the sarcolemma, appears to become more vulnerable to mechanical stress.
  • During the lowering phase of a lift, the eccentric phase, where the muscle is producing force while lengthening, the membrane is under a lot of mechanical load. In a healthy cell, it handles that stress and repairs. In a cell where those structural molecules have been depleted, the same load may cause disproportionate damage. This is based largely on animal and cell culture work, but it fits the pattern we see in patients.
  • It also helps explain something important: why statin myopathy appears to depend not just on the drug dose but on the training load. Two patients on the same statin at the same dose could have very different outcomes depending on how hard they’re training.
• Third: a brand-new piece of the puzzle, and this one’s from 2025.
  • Researchers using high-resolution imaging, a technique called cryo-electron microscopy, recently showed that statins can bind directly to a calcium release channel in skeletal muscle called the ryanodine receptor.
    • In plain terms: muscle cells keep calcium locked in a storage compartment and release it in a controlled way to trigger contractions. This receptor is the gate. When statins bind to it, the gate becomes leaky. Calcium seeps into the cell when it shouldn’t.
  • Excess calcium in a muscle cell is a problem.
    • It activates enzymes that break down proteins, generates damaging molecules called reactive oxygen species, and if the cell can’t pump the calcium back out fast enough, which requires energy it may already be short on, the damage compounds. One of the proteins activated by excess calcium is called atrogin-1. 
    • If that’s happening, the patient is caught in a tug of war: training is trying to build muscle, but the drug is accelerating protein breakdown. The net effect could be that strength and go backwards

• So if these mechanisms affect everyone on a statin, why don’t more people get myopathy?
  • This is the right question, and it’s one of the more interesting parts of the story. The biochemical changes, some degree of CoQ10 reduction, some degree of membrane effect, probably happen in most people taking statins.
    •  But for the vast majority, the body compensates. You have backup energy pathways, you have repair mechanisms, and the magnitude of the effect at typical doses just isn’t enough to cause symptoms.
    • What tips certain people over the edge appears to be a combination of factors.
      • Genetic variants play a role. 
      • That ryanodine receptor we just talked about? Some people carry gain-of-function variants that make the channel more prone to leaking, and those variants are overrepresented in people who develop statin intolerance. 
      • There’s also a liver transporter gene where a specific variant reduces how efficiently the body clears the statin, leading to higher blood levels of the drug. 
      • Older age, female sex, kidney disease, thyroid problems, drug interactions, and, relevant to our patient, exercise, all pile on top of the genetic baseline.
    • So the short answer is: the mechanism is probably always running at a low level, but it takes a specific combination of dose, genetics, and stress to push it past the threshold where it causes real damage.

• One more quick factoid on this, and it’s a good one for the nocebo conversation.
  • A 2018 study looked at the number of websites in different countries that discuss statin side effects and compared that to reported statin intolerance. 
  • The correlation was strong: countries with more online content about side effects had higher reported intolerance.
  • And in the ASCOT trial, muscle symptoms occurred at the same rate on statin versus placebo during the blinded phase. It was only during the open-label extension, when patients knew they were taking a statin, that reports jumped by about 41 percent.
  • There’s an even more elegant trial called SAMSON.
    • Sixty patients who’d previously quit statins because of side effects were given 12 months of randomized, blinded treatment: four months of statin, four months of placebo, four months of nothing. They tracked symptoms daily on a phone app. 
    • The result: about 90 percent of the symptom burden people attributed to the statin occurred equally on placebo. Statin months and placebo months were virtually identical. 
    • Both were worse than the no-tablet months, which tells you the act of taking a pill, any pill, was driving most of the symptoms. And here’s the kicker: after seeing their own data, half of these patients who’d sworn off statins successfully restarted them.
  • None of which means statin myopathy isn’t real. It is. We just spent the last ten minutes explaining the mechanisms. The point is that the reported rates are inflated by expectation, and the true pharmacological rate, meaning the excess above what placebo causes, is estimated at roughly 1 to 5 percent in controlled trials

• But you might see other numbers if you do your own research 
  •  the terminology here matters and it’s worth being precise.
  • Doctors use several terms that sound similar but mean different things.
    • Myalgia is muscle pain without CK elevation. 
    • Myositis is muscle pain with CK elevation, meaning there’s measurable muscle damage. 
    • Myopathy is the broader umbrella term that covers the whole spectrum. 
    • And rhabdomyolysis is the severe end, where CK is extremely elevated and the kidneys are at risk.
  • The problem is these terms get used interchangeably in the literature, which makes incidence numbers messy. If you define the outcome as “any muscle symptom at all,” including vague aching with no CK elevation, you get rates of 10 to 25 percent.
    • If you restrict it to objectively confirmed muscle damage with CK elevation, the number drops to well below 5%
    • Rhabdo w kidney involvement is less than 0.1%

Austin, how much detail about myositis and rhabdo risk do you go into with patients who may be starting a statin or combination therapy?

• That’s probably reasonable, especially given the data on statins and training outcomes specifically.
• This comes up a lot. The best data we have is from the STOMP trial:
  • 420 healthy, statin-naive people randomized to high-dose atorvastatin, 80 milligrams, versus placebo for six months. 
  • The result: no significant difference in muscle strength or exercise capacity between the two groups. CK did go up on average, about 21 units, which is small, and nobody exceeded 10 times the upper limit of normal. 
• Additional data shows statins amplify the CK response to exercise
  •  In one study, lovastatin users had 62 to 77 percent higher CK levels at 24 and 48 hours after eccentric exercise compared to placebo. 
• Endurance
  • we have limited evidence that statins, especially at higher doses, may reduce baseline muscle oxidative capacity and potentially blunt aerobic fitness gains from training.
    •  The data is mixed, dose-dependent, and mostly from small studies.
    • What we do know from larger outcome studies is that the combination of statin therapy and exercise produces better survival than either alone and CRF still improves
    • So the clinical takeaway hasn’t changed — train, take the medication if it’s indicated, and work with your doctor to find the lowest dose that hits the target. But it’s worth knowing the interaction exists, because it’s another reason to optimize dosing rather than just defaulting to the maximum.

So the picture that’s emerging is that statins don’t meaningfully impair training in the average user. But in the subset of susceptible people, and our patient was clearly in that subset, the combination of drug exposure, genetics, and training stress can cross a threshold where the damage is real and measurable.

Since we’re talking about muscles, medications, and metabolic syndrome, there’s one more thing worth keeping an eye on.

• Tirzepatide, the dual GIP/GLP-1 receptor agonist that most people know as a diabetes and weight loss drug, is generating some interesting cardiovascular data.
  • In addition to its metabolic effects, clinical trials have shown it can lower triglycerides by about 25 to 30 percent and reduce ApoB, which is the protein that rides on the cholesterol particles that build plaque. ApoB reduction is a meaningful signal because it tracks closely with cardiovascular risk.
  • A trial called T-Plaque is currently looking at whether tirzepatide directly slows coronary plaque progression and the early results are promising
  • The 2026 guidelines mention tirzepatide and semaglutide in the context of weight management with secondary lipid benefits, but they’re not yet positioned as primary lipid-lowering drugs. 
  • For patients who have overlapping metabolic, cardiovascular, and kidney risk, what the guidelines now call CKM syndrome, cardiovascular-kidney-metabolic syndrome, this drug class may eventually become another tool. 

Austin, what do you think about combining GLP1’s with statins and lifestyle interventions to optimize someone’s health relating to CKM syndrome? 

Segment 4 Who gets caught by this, and what’s the one test that tells you?

We’ve laid out the mechanism. Now: who’s most at risk, and what’s the one test that separates a drug problem from a programming problem?

• Statin-related muscle problems sit on a spectrum.
  • At the mild end, myalgia: aching and soreness without any CK elevation.
  • In the middle, myositis: pain with measurable muscle damage, meaning CK is elevated. 
  • At the severe end, rhabdomyolysis: massive CK, potential kidney injury.
• The early stages look identical to new-exerciser soreness. And we need to keep making this point: real, drug-caused statin myopathy is uncommon.
  •  In controlled trials where patients didn’t know whether they were on the drug or a placebo, the excess rate of muscle symptoms attributable to the statin was roughly 1 to 5 %. A meaningful portion of what patients report appears to be driven by expectation, the nocebo effect we talked about.
• Uncommon doesn’t mean zero.
  • And in certain subgroups, the risk is meaningfully higher. The 2026 guidelines specifically list vigorous exercise as a risk factor for statin-related muscle symptoms. To our knowledge, this is the first time it’s appeared in the risk factor section of a major lipid guideline.
• Here are the other risk factors the guidelines call out.
  • Drug combinations. Statin plus a fibrate, which is what our patient was on. Gemfibrozil carries the highest risk because of how directly it competes with statin metabolism in the liver. Fenofibrate is preferred when you need both, but it’s not risk-free.
  • Statin type. Fat-soluble statins like atorvastatin and simvastatin tend to cause more muscle problems than water-soluble ones like pravastatin or rosuvastatin. In one review, simvastatin accounted for 55 of 112 rhabdomyolysis cases, though that may partly reflect how widely it was prescribed at the time.
  • Drug interactions. Certain antibiotics, antifungals, calcium channel blockers, and grapefruit juice can all raise circulating statin levels by interfering with the enzyme that clears the drug from the body
  • Demographics. Older age, particularly over 65, and female sex both appear to increase risk based on observational data, though the exact magnitude varies across studies.
  • Genetics. There’s a liver transporter gene called SLCO1B1 with a specific variant that reduces statin clearance and raises blood levels. Genetic testing for it is available but still underused.
  • Other medical conditions. Hypothyroidism, kidney disease, liver disease, and both very high and very low BMI are all listed.
  • There’s also a very rare autoimmune variant worth knowing about. In rare cases, statins can trigger the immune system to produce antibodies against the enzyme the statin targets.
    •  At that point, the immune system is attacking muscle independently of the drug. A 2024 case report describes a patient whose CK was over 8,000 and didn’t come down after stopping the statin. It only improved after IV steroids. If CK stays elevated after the drug is stopped, this needs to be on the radar.

Austin, here’s what I want your take on. Given everything we’ve talked about, if a patient on a statin comes to you and says their strength is declining and they’ve got persistent soreness, walk me through what you’d do.

The heuristic I want listeners to take away: if you’re on a statin and you exercise regularly and you develop unexplained weakness, declining performance, or soreness that doesn’t follow the expected recovery timeline, get a CK drawn before changing anything about your training.

If CK is normal or mildly elevated and you’ve been training hard recently, it’s most likely exercise-related. If CK is more than 10 times the upper limit of normal and doesn’t come back down within 10 to 14 days of rest, that’s a conversation about the medication. And if CK is trending up, or you’ve got dark urine, rising creatinine, or weakness way out of proportion to your training, you should call your doctor urgently.

Segment 5 What happened to the patient, and what should you do if this is you?

Let’s close this out with what happened to the patient and what to do if this is you.

After discharge, the statin-fibrate combination was off the table going forward. He was put on alcohol abstinence, to follow the diet from our how-to-eat healthy article, and fish oil

Quick aside on the fish oil, because we’ve done a full episode on this.

Fish oil, specifically the omega-3 fatty acids EPA and DHA, can lower triglycerides by roughly 15 percent at standard supplement doses. That’s helpful, but for patients who need serious triglyceride reduction-like the one discussed here, over-the-counter fish oil isn’t usually enough. 

• The REDUCE-IT trial used a high-dose prescription form, icosapent ethyl, at 4 grams a day and saw a 25 percent reduction in cardiovascular events. The synthetic, purified EPA forms are what the data supports most strongly for cardiovascular outcomes.
• Standard fish oil supplementation, while it does lower triglycerides modestly, hasn’t shown the same robust benefit for reducing heart attacks and strokes in people who don’t already have high cardiovascular risk. 
• We still recommend 1 to 2 servings of oily fish per week for the overall package of benefits from food, but for pharmacological triglyceride lowering, the prescription forms appear to be better than OTC.

At the two-day follow-up, CK and transaminases were still elevated but trending in the right direction. One month later, CK and transaminases were normal. Lipids were improved: total cholesterol 238 and triglycerides 216, so still above target but moving. He was asymptomatic, exercising regularly with no recurrence, and had quit smoking. The formal diagnosis was drug-induced myositis, meaning the medication caused the muscle damage. 

So, What do the 2026 guidelines change for patients like this.

For patients who develop statin-related muscle problems and can’t reach their LDL target on a tolerable statin dose, the guidelines lay out a clear escalation. First-line options include reducing the statin dose and adding a non-statin drug: like bempedoic acid, ezetimibe, or a PCSK9 inhibitor.

Bempedoic acid may be worth explaining. It blocks a different enzyme in the same cholesterol production pathway, upstream of where statins work. The key difference is it’s what’s called a prodrug, meaning it’s inactive when you swallow it and only gets activated by an enzyme in the liver. Muscle cells don’t have that activating enzyme, so the drug doesn’t turn on there. In trials, bempedoic acid has shown significantly lower rates of muscle side effects compared to statins. For a patient like ours, bempedoic acid plus ezetimibe is a realistic path to LDL reduction without the same muscle risk.

The guidelines also now recommend measuring something called Lp(a), pronounced L-P-little-a, at least once in all adults. Lp(a) is a type of cholesterol particle that’s largely determined by your genes, and it independently increases cardiovascular risk. That recommendation is new. And for patients who truly can’t tolerate statins, the toolkit is the broadest it’s ever been: bempedoic acid, ezetimibe, PCSK9 inhibitors, a newer injectable called inclisiran. The goal is the LDL target. The specific drug is negotiable.

For clinicians.

When you prescribe a statin and counsel exercise, those two prescriptions can interact inside the muscle cell. Most patients tolerate both just fine. But the 2026 guidelines list vigorous exercise as a risk factor for statin-related muscle problems, and that should change the proactive conversation you have with patients who train.

Austin, I’m going to suggest considering a baseline CK in patients who exercise regularly before starting a statin. The guidelines say routine CK monitoring isn’t recommended for the general population, and that’s a reasonable position for sedentary patients. But a baseline CK costs almost nothing and gives you a reference point. If that patient starts a new program or ramps up intensity on a statin, a CK at 4 to 6 weeks is a reasonable safety net. Thots?

For patients and lifters.

If you’re on a statin and you train, that’s not a reason to stop either one. Statins reduce cardiovascular events. Exercise reduces all-cause mortality. The latest trial showed a 33 percent relative reduction in cardiovascular events at the more aggressive LDL target. Both interventions are worth preserving.

If you develop muscle pain, weakness, or dark urine that doesn’t track with your training, tell your doctor and ask for a CK. If it wasn’t clear from our Overtraining podcast, you probably shouldn’t accept overtraining as the default explanation. And make sure your doctor knows you exercise, what kind, and how often. Exercise habits are chronically underdocumented in medical charts, and your doctor may not be aware.

If your CK is elevated, a washout is a reasonable first step. Stop the statin for 2 to 4 weeks, rest from training for 10 to 14 days, then repeat the CK. If it normalizes, the statin was likely the issue. If it doesn’t, further evaluation is warranted, including testing for those autoimmune antibodies we talked about.

And if you’re statin-intolerant, you’re not stuck. The goal is the LDL target, not the specific drug. There are more ways to get there now than there used to be.

Austin, before I do the takeaways, anything you want to add? 

[After Austin’s closing thoughts]

Five takeaways.

One. Statin myopathy is real but relatively uncommon. The excess symptom rate above placebo in controlled trials is roughly 1 to 5 percent. But in exercising patients, especially on combination therapy, the risk is higher. 

Two. Three proposed mechanisms: reduced energy production from CoQ10 depletion, compromised muscle cell membranes from loss of structural molecules, and accelerated protein breakdown. Exercise amplifies all three, though the vast majority of people can compensate for these changes. Of note, CoQ10 supplementation is not supported by the current evidence.

Three. If you’re on a statin and your strength is declining, talk to your doctor before stopping the medication or changing your training. A CK test, amongst others, may be helpful in separating a drug problem from a programming problem.

Four. The 2026 guidelines list vigorous exercise as a risk factor for statin-associated muscle symptoms for the first time. They also give statin-intolerant patients a clear escalation: bempedoic acid, ezetimibe, PCSK9 inhibitors, and so on. There are options here.

Five. Lower is better for LDL. Thirty-three percent relative reduction in cardiovascular events at less than 55 versus 70 in the latest trial. Healthy lifestyle changes and getting on effective lipid-lowering therapy – if needed – are some of the best things you can do for cardiovascular risk.

That’s a wrap. Leave us a five-star rating and a review. It’s the best thing you can do so we can keep bringing you the latest nuance in health and fitness. I’m Dr. Jordan Feigenbaum. That’s Dr. Austin Baraki. We’ll catch you next week right here on the Barbell Medicine Podcast.